SCYNEXIS INC 8-K

What Happened
SCYNEXIS Inc. announced on March 30–31, 2026 that it entered into an Asset Purchase Agreement to acquire Poxel SA’s direct AMP‑activated protein kinase (AMPK) activator research and development program, including the compound known as PXL‑770. SCYNEXIS will pay a one‑time upfront cash payment of $8,000,000 within 30 days of the agreement and assumed certain post‑closing liabilities related to the acquired assets. The company also issued a press release and scheduled a conference call for March 31, 2026 to discuss the transaction.

Key Details

• Purchase date and filing: Asset Purchase Agreement executed March 30, 2026; 8‑K filed March 31, 2026.
• Upfront and milestones: $8,000,000 one‑time upfront payment plus up to $188,000,000 in contingent milestone payments tied to development and commercial events.
  • Examples of milestone triggers: $2M at first Phase 2 start; $6M at first Phase 3 start or first U.S. marketing approval; $25M at first U.S. commercial sale; laddered sales milestones up to $75M for ≥$1.5B calendar year sales.
• IP and license: SCYNEXIS acquired patents, know‑how, regulatory filings, inventory and related contracts for the AMPK program and received an exclusive, sublicensable, perpetual worldwide license under certain Poxel IP.
• Process and disputes: Agreement contains customary reps, covenants and indemnities, governed by New York law, with dispute escalation and ICC arbitration (seat in New York) if needed.

Why It Matters
This transaction adds Poxel’s AMPK activator program (including PXL‑770) to SCYNEXIS’s pipeline, potentially expanding its development portfolio and future commercial opportunities. The $8M upfront payment is a near‑term cash outlay; additional payments of up to $188M are contingent on clinical and sales milestones, meaning future cash obligations depend on program progress and commercial success. Investors should watch subsequent clinical updates, regulatory progress, and how SCYNEXIS finances and integrates the acquired program.